|
Corpora |
||||||
| AIMed |
BioInfer |
HPRD50 |
IEPA |
LLL |
||
|
|
||||||
| size |
1955 |
1100 |
145 |
486 |
77 |
|
|
|
||||||
| Entity |
scope |
human P/G |
P/G/R and related |
human P/G |
Chemicals |
P/G |
| coverage |
all occurrences |
all occurrences |
NER system |
list of 16 names |
list of 116 names |
|
| types |
no |
111 types (ontology) |
no |
no |
P/G |
|
|
|
||||||
| PPI |
types |
no |
68 types (ontology) |
no |
no |
3 types |
| binding |
no |
yes |
no |
yes |
no |
|
| directed |
no |
yes |
no |
yes |
yes |
|
| complex |
no |
yes |
no |
no |
no |
|
| negative |
no |
yes |
no |
no |
no |
|
| certainty |
no |
no |
yes |
no |
no |
|
|
Legend: Size: Number of sentences in the corpus Entity scope: Types of the named entities identified in the corpus: (P)rotein, (G)ene, (R)NA Entity coverage: Coverage of in-scope entity occurrences in each sentence Entity types: Explicit identification of the type of the annotated named entity occurrences PPI types: Explicit indication of the type of the annotated interactions PPI binding: Identification of the specific text spans that entail the annotated interactions PPI directed: Specification of the directionality of the interaction (typically identification of agent vs. patient roles) PPI complex: Annotation includes nested or n-ary (for n > 2) interactions PPI negative: Annotation of negative interactions PPI certainty: Annotation of the levels of certainty, or speculativeness, of interactions | ||||||
Pyysalo et al. BMC Bioinformatics 2008 9(Suppl 3):S6 doi:10.1186/1471-2105-9-S3-S6 |
||||||